Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book
  1. Brieflands
  2. journals
  3. Koomesh
  4. Articles

  5. Comparing adverse effects of docetaxel-doxorubicin and paclitaxel-doxorubicin regimens in breast cancer patients
  6. Scopus by Title (Ref)

Koomesh

Journal of Semnan University of Medical Sciences

homeHome
listAll Issuesplay_arrowIn Presscheck_circleAccepted ManuscriptssearchSearch
lightbulbInstructions
infoJournal InformationgroupsEditors & BoardspublicIndexing and Listing Sourcesquery_statsJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Publication Malpractice Statementassignment_indReviewer and AE Registration FormchatSupportphone_in_talkContact Us
euroAPC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Effect of endurance training and the consumption of gallic acid and Kaempferol on the expression of ARC, VEGFα, HIF1α, and CREB1 genes in mice with breast cancer treated with paclitaxel

- Malekpoor Z. , et al.

2. The Effect of Aerobic Exercise Combined with the Combination of Gallic Acid and Kaempferol on Neurogenesis Caused by the Side Effects of Paclitaxel in Mice with Breast Cancer

- Malekpoor Z. , et al.

HomeInstructionsAPC

Articles

  • All Issues
  • In Press
  • Accepted Manuscripts
  • Search

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Publication Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.